REG-Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Oculis will present Phase 2 ACUITY data and an overview of the Privosegtor PIONEER registrational program at the APOIS Congress in Seoul and the CNS Summit in Boston. ACUITY showed improvements in visual function, retinal preservation, and reduced blood neurofilament levels in acute optic neuritis, supporting Breakthrough Therapy and PRIME designations for Privosegtor.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- Ind clearance expected
- acute multiple sclerosis relapses IND expected Q4 2026
- Registrational program
- PIONEER (two registrational trials in optic neuritis, one in NAION)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.